Real-world evidence (RWE) shows good acceptance of rituximab biosimilar in non-Hodgkin lymphoma (NHL)

  • The retrospective study, published in Future Oncology, is one of the first to investigate the acceptance of rituximab biosimilars in the United States in an oncology setting and the first study to examine real-world data for rituximab-pvvr [biosimilar]
  • Although rituximab-pvvr was only recently introduced to market, the preliminary results suggest that this medication is being accepted in US oncology practice and is being used in a manner consistent with clinical guidelines in which the use of rituximab is recommended as part of a combination regimen with chemotherapy, targeted therapy, or immunotherapy
  • Oncology biosimilars have the potential to improve patient access to treatments and reduce biologics spending by $44 billion over a 10-year period

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit and contact us at

ref: SEP2021BR002